Life expectancy reduced about 2 years by low Vitamin D or average air pollution

Low vs high vitamin D and life expectancy — how many years?

Short answer: There is enough data to estimate it, and the credible range is 1–3 years for a genuinely deficient person brought up to a replete level. Dr. Grant's widely-cited ~2 years sits squarely in that range — but it is best read as an upper-bound, population-average figure that assumes the full association is causal. The honest estimate is conditional: most of the lifespan benefit is in correcting deficiency, not in pushing already-adequate levels higher.

Where the "2 years" comes from — Grant 2011

Grant's figure comes from a model of doubling serum 25(OH)D from 54 to 110 nmol/L. He estimated all-cause mortality reductions of 7.6% (African females) to 17.3% (European females), and a ~2-year life-expectancy gain across all six world regions studied. It is an ecological/observational model, so it represents the ceiling — what you would see if the entire observed association were causal and reversible.

Grant WB. An estimate of the global reduction in mortality rates through doubling vitamin D levels. Eur J Clin Nutr. 2011;65(9):1016–26. PMID 21731036.

The evidence in three tiers

Tier 1 — Observational: large, consistent, but confounded

The raw association is robust and reproducible. A standardized three-cohort analysis found all-cause mortality rose ~20% per 20 nmol/L decrease in 25(OH)D (HR 1.20, 95% CI 1.15–1.25). Compounded across a deficient-vs-replete gap (~25 vs ~100 nmol/L) this implies roughly a doubling of mortality risk. (Note: 25 nmol/L ≈ 10 ng/mL, 50 ≈ 20, 100 ≈ 40)

Caveat: reverse causation and confounding inflate this. Frail, obese, ill, and housebound people have low 25(OH)D because of their condition, so observational data overstates the causal effect.

Tier 2 — Mendelian randomization: causal, but only at the low end

MR uses genetic variants to get past confounding, and it is the most decision-relevant tier here.

  • UK Biobank nonlinear MR (~307,000 people, 18,700 deaths): an L-shaped relationship — mortality risk fell steeply as genetically-predicted 25(OH)D rose up to ~50 nmol/L, then flattened. Benefit is concentrated in correcting deficiency; raising already-adequate levels showed no further gain.
  • Three-cohort standardized MR: directionally consistent (HR ~1.32–1.35 per 20 nmol/L of genetically lower 25(OH)D) but underpowered, with wide confidence intervals.

Caveat to flag: the large Lancet Diabetes & Endocrinology MR paper on this topic was retracted and republished over methodology, though its core conclusion (effect concentrated in the low-25(OH)D strata) survived.

Tier 3 — Randomized controlled trials: null for all-cause, modest for cancer death

The highest tier of evidence — and the reality check. Supplementation trials, run overwhelmingly in already-replete populations, show no significant all-cause mortality benefit. The one consistent positive signal is cancer mortality, and only with daily (not bolus) dosing:

  • Individual-patient-data meta-analysis: overall non-significant 6% reduction (HR 0.94, 95% CI 0.86–1.02); significant ~12% reduction restricted to daily-dosing trials.
  • Earlier RCT meta-analysis: ~13% lower cancer mortality with daily dosing, corresponding to ~7% lower total mortality.
  • VITAL: cancer-mortality benefit strengthened to RR 0.75 when the first two years of follow-up were excluded.

This reinforces the "Bolus is Bogus" pattern: dosing frequency, not just dose, drives the mortality signal.

Reconciling the tiers

The apparent contradiction — strong observational/MR signal, null RCT all-cause result — is largely a design artifact: the RCTs tested "more on top of enough," while MR shows the action is below ~50 nmol/L. So the defensible estimate is conditional, not a single universal number:

Scenario Estimated lifespan effect Strength of evidence
Genuinely deficient → replete ~1–3 years gained (Grant's 2 yr a reasonable midpoint) Observational + MR support causality at this end
Already adequate → higher still Little to none L-shaped MR + null RCTs
  • "This linear extrapolation overstates, since the effect flattens above ~50 nmol/L (see Tier 2)"

How vitamin D ranks against other chronic stressors

Slotting the deficient-vs-replete estimate into the life-expectancy ranking of environmental stressors puts it in striking company:

Stressor Average life expectancy at stake Confidence Voluntarily correctable?
Heavy air pollution (polluted megacity) up to ~10 yr; ~2.3 yr global avg High Hard
Vitamin D deficiency → replete ~1–3 yr (≈2) Moderate; causal at low end Yes, cheaply
Living near a highway ~8–9 months Moderate Partly
Air pollution (typical developed city) ~7–8 months High Hard
Noise pollution (heavily exposed) weeks Moderate Partly
Roundup — farmers/applicators unquantified, likely small Low / contested Partly
Microplastics unquantified Very low / emerging No
Golf-course proximity unquantified Very low —

Headline: if the deficient-vs-replete difference is ~2 years and substantially causal, vitamin D deficiency is in the same lifespan league as heavy air pollution — and well above noise, microplastics, glyphosate, or highway proximity. Unlike all of those, it is cheaply and voluntarily correctable, and the correction is concentrated exactly where the causal evidence is strongest.

What this does NOT show — honest limits

  • It does not show that supplementing an already-replete person adds years. The trials and the L-shaped MR both argue against it.
  • It does not prove the full observational 2-year gap is causal; the causal core is the deficiency end.
  • All-cause mortality RCTs are null — the affirmative mortality evidence rests on cancer-mortality subgroups (daily dosing) plus MR, not on a positive all-cause trial result.
  • "1–3 years" is a population-average estimate and predicts no individual's outcome.

References

  1. Grant WB. An estimate of the global reduction in mortality rates through doubling vitamin D levels. Eur J Clin Nutr. 2011;65(9):1016–1026. PMID 21731036.
  2. Vitamin D deficiency increases mortality risk in the UK Biobank: a nonlinear Mendelian randomization study. Ann Intern Med. 2022;175(11):1552–1559. doi:10.7326/M21-3324.
  3. Effect of genetically low 25-hydroxyvitamin D on mortality risk: Mendelian randomization analysis in 3 large European cohorts. Nutrients. 2019;11(1):74. https://doi.org/10.3390/nu11010074
  4. Sofianopoulou E, et al. Estimating dose–response relationships for vitamin D with CHD, stroke, and all-cause mortality (observational and Mendelian randomization). Lancet Diabetes Endocrinol. 2021 (retraction and republication; see PMC7615586).
  5. Keum N, et al. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of RCTs. Ann Oncol. 2019;30(5):733–743. (Cancer-mortality RR 0.87, driven by daily dosing.)
  6. Individual-patient-data meta-analysis of vitamin D3 and cancer mortality (overall HR 0.94; daily-dosing subgroup ~12% reduction). J Steroid Biochem Mol Biol. 2023. doi:10.1016/j.jsbmb.2023.106308.
  7. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer. 2014;111:976–980. (Cancer-mortality RR 0.88.)

Related in VitaminDWiki

Air Pollution

Low Vitamin D

Dr. Grant